Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory ...

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Merck & Co, known as MSD outside of the USA and Canada, today announced that the European Commission (EC) has approved a new ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

Industry analyst GlobalData has highlighted the significance of US pharma major Merck's (NYSE: MRK) plan to buy US biotech ...

Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults with post- and precapillary pulmonary hypertension due to heart failure. The Rahway, N.J., ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has ...

Cancer treatment drug Pembroria, which has the same active ingredient as Keytruda but is cheaper, has been licensed for ...

Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines ...